Last $1.40 USD
Change Today +0.06 / 4.48%
Volume 2.5M
DNDN On Other Exchanges
Symbol
Exchange
DNDN is not on other exchanges.
As of 8:10 PM 08/26/14 All times are local (Market data is delayed by at least 15 minutes).

dendreon corp (DNDN) Snapshot

Open
$1.33
Previous Close
$1.34
Day High
$1.43
Day Low
$1.33
52 Week High
12/19/13 - $3.52
52 Week Low
08/13/14 - $1.24
Market Cap
224.4M
Average Volume 10 Days
2.9M
EPS TTM
$-1.11
Shares Outstanding
160.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DENDREON CORP (DNDN)

dendreon corp (DNDN) Related Businessweek News

No Related Businessweek News Found

dendreon corp (DNDN) Details

Dendreon Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Its product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating various types of cancers. The company offers PROVENGE, an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, and castrate-resistant prostate cancer. Its product candidates under research and development includes DN24-02, an investigational active cellular immunotherapy, which is in Phase II clinical trial for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; carbonic anhydrase 9, an antigen expressed in renal cell carcinoma; carcinoembryonic antigen, an antigen expressed in colorectal and other cancers; and Transient Receptor Potential, sub-family M 8, a small molecule that has completed Phase I clinical trial to treat various types of cancers. Dendreon Corporation was founded in 1992 and is headquartered in Seattle, Washington.

710 Employees
Last Reported Date: 08/11/14
Founded in 1992

dendreon corp (DNDN) Top Compensated Officers

Interim Chief Financial Officer, Principal Ac...
Total Annual Compensation: $354.1K
Compensation as of Fiscal Year 2013.

dendreon corp (DNDN) Key Developments

Dendreon Reports Earnings Results for the Second Quarter of 2014

Dendreon reported earnings results for the second quarter of 2014. For the quarter, the company posted a net loss of $15.3 million, or $0.10 per share, compared with a prior-year net loss of $68.8 million, or $0.45 per share. Total revenue climbed 12% to $82.2 million.

Dendreon Corporation Announces Executive Changes

Dendreon Corporation announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the company's board of directors. Mr. Amick succeeds John H. Johnson, who previously announced his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson will work with Mr. Amick through August 15, 2014 to ensure a smooth transition. Mr. Amick brings to Dendreon significant experience within the pharmaceutical and life sciences industry. Most recently from 2010 to 2012, he served as chairman and chief executive officer of Discovery Labs. Prior to that, Mr. Amick enjoyed a highly successful 30-year career with Johnson & Johnson where, as vice president of the Ortho Biotech Oncology Franchise.

The U.S. District Court for the Western District of Washington Dismisses Securities Fraud Claims Against Dendreon Corp

The U.S. District Court for the Western District of Washington dismissed securities fraud claims while denying a motion to dismiss related state law claims brought by investors against Dendreon Corp. arising from statements made by the firm concerning the market position of a prostate cancer treatment offered by the firm. Thirty investors in Dendreon Corp. sued the company and certain of its officers, alleging violations of 10(b), 20(a) and 20A of the Securities Exchange Act of 1934, common law fraud and negligent misrepresentation. In a prior order, the court dismissed the complaint without prejudice, and the case came before the court on the defendants' motion to dismiss the second amended complaint. The court noted Provenge was a first-in-class immunotherapy that involved removing and culturing a patient's blood cells into order to strengthen their immune response and then reintroducing the strengthened cells into the patient's body. The complaint alleged the defendants made misrepresentations concerning physician reimbursement concerns, capacity constraints and "on-track" statements relating to the firm's expected growth trajectory. The court held the allegation that the Dendreon board was informed of a survey of potential Provenge providers showing that 65% had medium or low confidence that they would be reimbursed if they prescribed Provenge, which sold for $93,000 for a three-infusion treatment. The board was also informed that over 14% of providers that performed a Provenge infusion in 2010 had not yet scheduled one in 2011 because of reimbursement concerns or errors. The court found those allegations, while probative of scienter, were not sufficient under a holistic analysis to support a finding that the defendants acted with scienter in failing to publicly reveal the firm's concerns related to physician reimbursement. The court separately held the amended complaint failed to present new facts supporting the plaintiffs' argument that the defendants falsely represented that capacity constraints were affecting sales, when in fact the company was experiencing no capacity constraints, but was experiencing lackluster sales. Because the court found the same allegations insufficient to support scienter in evaluating the original complaint, the court similarly held that claim was inadequately alleged. The court noted the defendants made only a cursory argument that the court should also dismiss the plaintiffs' state law claims. The defendants' argument consisted of a single paragraph, and the court found that did not sufficiently address the claims alleged. Accordingly, the court granted the defendants' motion to dismiss the plaintiffs' securities fraud claims, while denying the defendants' motion to dismiss the plaintiffs' state law claims.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DNDN:US $1.40 USD +0.06

DNDN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amarin Corp PLC $1.90 USD +0.06
Pfizer Ltd/India 1,438 INR +32.10
Rigel Pharmaceuticals Inc $2.72 USD +0.05
Spectrum Pharmaceuticals Inc $8.15 USD +0.16
Wyeth Ltd 967.05 INR +37.65
View Industry Companies
 

Industry Analysis

DNDN

Industry Average

Valuation DNDN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DENDREON CORP, please visit www.dendreon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.